Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD

Kidney International

Volumn 75, Issue 2, 2009, Pages 139-141

  Chapman, Arlene B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

AUTOSOMAL DOMINANT DISORDER; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; IMAGE ANALYSIS; INTERRATER RELIABILITY; INTRARATER RELIABILITY; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR GROWTH;

EID: 58149156500     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.596     Document Type: Note

References (6)

1. Kistler AD, Poster D, Krauer F et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 205-213.
2. Grantham JJ, Torres VE, Chapman AB et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130.
3. Antiga L, Piccinelli M, Fasolini G et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 2006; 1: 754-760.
4. Kalb B, Votow JR, Salman K et al. Magnetic resonance nephrourography: current and developing techniques. Radiol Clin North Am 2008; 46: 11-24.
5. King BF, Torres VE, Brummer ME et al. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 2214-2221.
6. Rahbari F, Rizk D, Ladson J et al. Heritability (h2) of disease severity in autosomal dominant polycystic kidney disease (ADPKD): genetic contributions to renal volume (RV) measures. J Am Soc Nephrol 2004; 15: 660A.